Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02236312 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 359
- Enrollment target
NCT02236312 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 359 participants.
The verdict
NCT02236312, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 359 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the efficacy in wrinkle reduction of a single treatment of three different doses of botulinum toxin compared to placebo, in the treatment of moderate to very severe glabellar frown lines.
Interventions
- DRUG Placebo
- DRUG Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02236312
The ClinicalTrials.gov registry entry for NCT02236312 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02236312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02236312 about?
NCT02236312 is a clinical study titled "Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines". The primary objective of the study is to evaluate the efficacy in wrinkle reduction of a single treatment of three different doses of botulinum toxin compared to placebo, in the treatment of moderate to very severe glabellar frown lines.
What is the current status of trial NCT02236312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 359 participants. The study started on 2014-09. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02236312?
The interventions under investigation include: Placebo (DRUG), Botulinum Toxin Type A (DRUG).
Who is sponsoring clinical trial NCT02236312?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.